Literature DB >> 30707412

Banxia Xiexin Decoction () Combined with Afatinib in Treatment of Advanced Gallbladder Cancer: Case Report and Literature Review.

Li Su1, Miao-Miao Wang1, Meng-Ran Xu1, Xiao Wang2, Hong-Zhen Xia3, Mei Zhang1, Lei Zheng1, Yao-Dong Zhu1, Ming-Qi Wang1, Ping Li4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30707412     DOI： 10.1007/s11655-019-3152-1

Source DB:  PubMed          Journal:  Chin J Integr Med        ISSN： 1672-0415            Impact factor:   1.978


× No keyword cloud information.
  21 in total

Review 1.  Gallbladder cancer: can newer insights improve the outcome?

Authors:  Usha Dutta
Journal:  J Gastroenterol Hepatol       Date:  2012-04       Impact factor: 4.029

Review 2.  State-of-the-art in the management of locally advanced and metastatic gallbladder cancer.

Authors:  Mairéad G McNamara; Cristiane Metran-Nascente; Jennifer J Knox
Journal:  Curr Opin Oncol       Date:  2013-07       Impact factor: 3.645

3.  Decade in review-targeted therapy: successes, toxicities and challenges in solid tumours.

Authors:  Joel W Neal; George W Sledge
Journal:  Nat Rev Clin Oncol       Date:  2014-10-07       Impact factor: 66.675

4.  Banxia xiexin decoction protects against dextran sulfate sodium-induced chronic ulcerative colitis in mice.

Authors:  Gang Chen; Yang Yang; Moli Liu; Zhiying Teng; Juan Ye; Yuehua Xu; Xueting Cai; Xiaolan Cheng; Jie Yang; Chunping Hu; Min Wang; Peng Cao
Journal:  J Ethnopharmacol       Date:  2015-03-17       Impact factor: 4.360

5.  [Study on effect of different compatibility of saponins contained in banxia xiexin tang on intestinal bacterium metabolism].

Authors:  Juan Xiao; Yi-Fan Zhang; Ying Wang; Rui An; Xin-Hong Wang
Journal:  Zhongguo Zhong Yao Za Zhi       Date:  2013-02

6.  Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway.

Authors:  Maolan Li; Zhou Zhang; Xiaoguang Li; Junyi Ye; Xiangsong Wu; Zhujun Tan; Chang Liu; Baiyong Shen; Xu-An Wang; Wenguang Wu; Daizhan Zhou; Di Zhang; Ting Wang; Bingya Liu; Kai Qu; Qichen Ding; Hao Weng; Qian Ding; Jiasheng Mu; Yijun Shu; Runfa Bao; Yang Cao; Peizhan Chen; Tianyu Liu; Lin Jiang; Yunping Hu; Ping Dong; Jun Gu; Wei Lu; Weibin Shi; Jianhua Lu; Wei Gong; Zhaohui Tang; Yong Zhang; Xuefeng Wang; Y Eugene Chin; Xiaoling Weng; Hong Zhang; Wei Tang; Yonglan Zheng; Lin He; Hui Wang; Yun Liu; Yingbin Liu
Journal:  Nat Genet       Date:  2014-07-06       Impact factor: 38.330

7.  Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker.

Authors:  Flavio Solca; Goeran Dahl; Andreas Zoephel; Gerd Bader; Michael Sanderson; Christian Klein; Oliver Kraemer; Frank Himmelsbach; Eric Haaksma; Guenther R Adolf
Journal:  J Pharmacol Exp Ther       Date:  2012-08-10       Impact factor: 4.030

8.  Dramatic response to trastuzumab and paclitaxel in a patient with human epidermal growth factor receptor 2-positive metastatic cholangiocarcinoma.

Authors:  Lisa Y Law
Journal:  J Clin Oncol       Date:  2012-07-30       Impact factor: 44.544

Review 9.  Chemotherapy for the biliary tract cancers: moving toward improved survival time.

Authors:  Adriana Romiti; Chiara D'Antonio; Angelo Zullo; Ida Sarcina; Roberta Di Rocco; Viola Barucca; Valeria Durante; Paolo Marchetti
Journal:  J Gastrointest Cancer       Date:  2012-09

Review 10.  Gallbladder cancer: epidemiology and outcome.

Authors:  Rajveer Hundal; Eldon A Shaffer
Journal:  Clin Epidemiol       Date:  2014-03-07       Impact factor: 4.790
View more
  2 in total

1.  Banxia Xiexin Decoction Inhibits the Expression of PD-L1 Through Multi-Target and Multi-Pathway Regulation of Major Oncogenes in Gastric Cancer.

Authors:  Xuan Feng; Feng Xue; Guihua He; Suiping Huang; Qing Ni
Journal:  Onco Targets Ther       Date:  2021-05-19       Impact factor: 4.147

2.  Banxia xiexin decoction affects drug sensitivity in gastric cancer cells by regulating MGMT expression via IL‑6/JAK/STAT3‑mediated PD‑L1 activity.

Authors:  Xuan Feng; Feng Xue; Guihua He; Qing Ni; Suiping Huang
Journal:  Int J Mol Med       Date:  2021-07-19       Impact factor: 4.101
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.